<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01832168</url>
  </required_header>
  <id_info>
    <org_study_id>AFRALP001</org_study_id>
    <nct_id>NCT01832168</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial Using Amniotic Membrane in Robotic Assisted Laparoscopic Prostatectomy</brief_title>
  <official_title>A Prospective Randomized Clinical Trial Using Amniotic Membrane in Robotic Assisted Laparoscopic Prostatectomy (RALP)- Effect on Nerve Protection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MiMedx Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MiMedx Group, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the AmnioFix dehydrated human amniotic
      membrane is effective in protecting nerves in men receiving robotic assisted laparoscopic
      prostatectomies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients achieving return to baseline Sexual Health Inventory for Men (SHIM) score in the AmnioFix group versus the Control group.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to return of erectile function.</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores.</measure>
    <time_frame>10 days, 4 weeks, 3 months, and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Pudendal Nerve</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Robotic Assisted Laparoscopic Prostatectomy with application of absorbable hemostat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AmnioFix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Robotic Assisted Laparoscopic Prostatectomy with application of dehydrated human amniotic membrane.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Robotic Assisted Laparoscopic Prostatectomy</intervention_name>
    <description>Robotic Assisted Laparoscopic Prostatectomy with nerve-sparing technique</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>AmnioFix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Application of Absorbable Hemostat</intervention_name>
    <description>Application of Surgicel® SNoW Absorbable Hemostat by Johnson and Johnson on the neurovascular bundle after removal of the cancerous prostate.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Surgicel® SNoW</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Application of dehydrated human amniotic membrane</intervention_name>
    <description>Application of dehydrated human amniotic membrane (DHAM) on the neurovascular bundle after removal of the cancerous prostate.</description>
    <arm_group_label>AmnioFix</arm_group_label>
    <other_name>AmnioFix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages 45-70

          2. Clinically localized prostate cancer with Gleason score 6 or 7

          3. SHIM Score greater than or equal to 16 in the absence of medication

          4. Feasibility to perform unilateral or bilateral nerve sparing RALP

        Exclusion Criteria:

          1. Clinically locally advanced cancer and/or with Gleason score 8 or 9.

          2. Difficulty performing nerve sparing RALP.

          3. Prior surgery at the site.

          4. Site exhibits clinical signs and symptoms of infection.

          5. SHIM score at screening &lt;16.

          6. Current use of anticoagulant medication including Coumadin, Plavix, etc.

          7. Has had &quot;salvage prostatectomy&quot; - patients who failed prior therapies including
             external radiation therapy, cryotherapy, etc.

          8. Has prior radiation therapy treatment at the site.

          9. Prior hormonal therapy such as Lupron or oral anti-androgens.

         10. Non-mobile, i.e. not ambulatory or bed ridden.

         11. The presence of comorbidities that can be confused with or can exacerbate the
             condition including:

               1. diabetes

               2. advanced atherosclerotic vascular disease

         12. Patients with a history of more than two weeks treatment with immuno-suppressants
             (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to
             initial screening, or who receive such medications during the screening period, or who
             are anticipated to require such medications during the course of the study.

         13. Patients on any investigational drug(s) or therapeutic device(s) within 30 days
             preceding screening.

         14. Unable to comply with penile rehabilitation.

         15. Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV.

         16. Patients who are unable to understand the aims and objectives of the trial.

         17. Presence of any condition(s) which seriously compromises the subject's ability to
             complete this study, or has a known history of poor adherence with medical treatment.

         18. Currently taking medications which could affect graft incorporation (supervising
             physician's discretion).

         19. Allergic to gentamicin and/or streptomycin.

         20. Damage to neurovascular bundles during surgery.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Razdan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jackson South Urology Center of Excellence</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jackson South Urology Center of Excellence</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2013</study_first_submitted>
  <study_first_submitted_qc>April 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2013</study_first_posted>
  <last_update_submitted>March 16, 2015</last_update_submitted>
  <last_update_submitted_qc>March 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

